Botox, fillers steal the show as Allergan posts Q2 beats
admin 3rd August 2017 Uncategorised 0Allergan’s catching a break this year, and it’s one that Thursday allowed it to hike its guidance for 2017. The company’s new 2017 sales range of $15.85 billion to $16.05 billion, up from $15.8 billion to $16 billion, reflects that the drugmaker doesn’t expect to see a generic of its Namenda XR hit until the first quarter of next year.
More: Botox, fillers steal the show as Allergan posts Q2 beats
Source: fierce